MoonLake Immunotherapeutics (MLTX) Expected to Announce Earnings on Thursday

MoonLake Immunotherapeutics (NASDAQ:MLTX) is expected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect MoonLake Immunotherapeutics to post earnings of ($0.89) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 13, 2025 at 7:00 AM ET.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same period in the prior year, the firm earned ($0.39) EPS. On average, analysts expect MoonLake Immunotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MoonLake Immunotherapeutics Stock Up 1.0%

NASDAQ:MLTX opened at $10.20 on Tuesday. The company has a market cap of $655.15 million, a PE ratio of -3.67 and a beta of 1.13. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The company has a current ratio of 16.65, a quick ratio of 16.65 and a debt-to-equity ratio of 0.21. The company’s 50 day moving average is $31.54 and its two-hundred day moving average is $41.11.

Insider Activity at MoonLake Immunotherapeutics

In other news, major shareholder Bihua Chen sold 5,827 shares of the company’s stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $6.96, for a total value of $40,555.92. Following the sale, the insider directly owned 1,994,173 shares of the company’s stock, valued at $13,879,444.08. This represents a 0.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.05% of the stock is owned by company insiders.

Institutional Trading of MoonLake Immunotherapeutics

Large investors have recently made changes to their positions in the business. Millennium Management LLC boosted its holdings in MoonLake Immunotherapeutics by 3,343.2% during the first quarter. Millennium Management LLC now owns 344,320 shares of the company’s stock worth $13,453,000 after buying an additional 334,320 shares in the last quarter. Geode Capital Management LLC boosted its holdings in MoonLake Immunotherapeutics by 0.9% during the second quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock worth $2,809,000 after buying an additional 559 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in MoonLake Immunotherapeutics by 4,584.5% during the second quarter. JPMorgan Chase & Co. now owns 39,397 shares of the company’s stock worth $1,860,000 after buying an additional 38,556 shares in the last quarter. Legal & General Group Plc boosted its holdings in MoonLake Immunotherapeutics by 7.3% during the second quarter. Legal & General Group Plc now owns 20,905 shares of the company’s stock worth $987,000 after buying an additional 1,425 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in MoonLake Immunotherapeutics during the second quarter worth $593,000. 93.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Wedbush dropped their target price on shares of MoonLake Immunotherapeutics from $80.00 to $18.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 30th. Stifel Nicolaus downgraded shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 target price on the stock. in a research report on Monday, September 29th. Citigroup downgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $7.00 price objective on shares of MoonLake Immunotherapeutics in a report on Wednesday, October 1st. Four equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $30.17.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.